BA
ABBV icon

Bridgewater Associates’s AbbVie ABBV Stock Holding History

Bridgewater Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.96M Sell
11,775
-18,587
-61% -$4M 0.01% 595
2026
Q1 		$6.6M Buy
30,362
+16,153
+114% +$3.58M 0.03% 349
2025
Q4 		$3.25M Sell
14,209
-246,480
-95% -$56.1M 0.01% 652
2025
Q3 		$60.4M Sell
260,689
-337,603
-56% -$68.7M 0.24% 76
2025
Q2 		$111M Buy
598,292
+493,340
+470% +$91.7M 0.45% 51
2025
Q1 		$22M Sell
104,952
-181,411
-63% -$35.3M 0.1% 168
2024
Q4 		$50.9M Buy
286,363
+81,791
+40% +$15M 0.23% 81
2024
Q3 		$40.4M Sell
204,572
-83,953
-29% -$15.7M 0.23% 81
2024
Q2 		$49.5M Sell
288,525
-161,254
-36% -$26.7M 0.26% 64
2024
Q1 		$81.9M Sell
449,779
-157,114
-26% -$27.1M 0.41% 47
2023
Q4 		$94.1M Buy
606,893
+30,933
+5% +$4.51M 0.53% 41
2023
Q3 		$85.9M Sell
575,960
-58,345
-9% -$8.57M 0.52% 39
2023
Q2 		$85.5M Buy
634,305
+222,875
+54% +$32.7M 0.53% 40
2023
Q1 		$65.6M Buy
411,430
+381,328
+1,267% +$58.3M 0.4% 54
2022
Q4 		$4.86M Sell
30,102
-182,648
-86% -$28M 0.03% 366
2022
Q3 		$28.6M Buy
212,750
+130,900
+160% +$18.8M 0.14% 125
2022
Q2 		$12.5M Buy
81,850
+6,334
+8% +$968K 0.05% 287
2022
Q1 		$12.2M Buy
75,516
+33,661
+80% +$4.89M 0.05% 253
2021
Q4 		$5.67M Sell
41,855
-33,241
-44% -$3.93M 0.03% 269
2021
Q3 		$8.1M Buy
75,096
+22,491
+43% +$2.57M 0.04% 223
2021
Q2 		$5.92M Buy
+52,605
New +$5.92M 0.04% 303
2021
Q1 		– Sell
-25,294
Closed -$2.71M – 458
2020
Q4 		$2.71M Buy
+25,294
New +$2.43M 0.02% 265

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bridgewater Associates's ABBV Position: Q2 2026 in Review

Bridgewater Associates reduced its AbbVie (ABBV) stake by 61% in Q2 2026, selling an estimated $4M and leaving 11,775 shares worth $2.96M. The position accounts for 0.01% of the portfolio, ranked #595.

Bridgewater Associates first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $111M in Q2 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Bridgewater Associates held 11,775 shares of AbbVie worth $2.96M as of Q2 2026.
  • Bridgewater Associates sold 18,587 AbbVie shares in Q2 2026, an estimated $4M.
  • AbbVie made up 0.01% of Bridgewater Associates's portfolio in Q2 2026, its #595 holding.
  • Bridgewater Associates first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
  • Bridgewater Associates's AbbVie position peaked at $111M in Q2 2025.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.